Fertilo
Improving IVF and egg freezing outcomes (ex vivo oocyte maturation)
Phase 3Active
Key Facts
Indication
Improving IVF and egg freezing outcomes (ex vivo oocyte maturation)
Phase
Phase 3
Status
Active
Company
About Gameto
Gameto is a private, clinical-stage biotech founded in 2020, leveraging a proprietary induced pluripotent stem cell (iPSC) platform to engineer ovarian support cells. Its lead asset, Fertilo, is in Phase 3 trials for improving IVF outcomes, while earlier-stage programs target ovarian disease (Deovo) and menopause (Ameno). The company is backed by venture capital and a recent award from ARPA-H, positioning it at the forefront of innovation in the underserved women's health market.
View full company profile